AIMS: To evaluate whether the potent CYP3A4 inhibitor ketoconazole has any influence on the pharmacokinetic and electrocardiographic parameters of the antimalarial co-artemether (artemether-lumefantrine) in healthy subjects. METHODS:Sixteen subjects were randomized in an open-label, two period crossover design study. Subjects received a single dose of co-artemether (day 1) either alone or in combination with multiple oral doses of ketoconazole (400 mg on day 1 followed by 200 mg o.d. for 4 additional days). Serial blood samples were taken and assayed for artemether and its main active metabolite dihydroartemisinin (DHA), and lumefantrine. RESULTS: The pharmacokinetics of artemether, its metabolite DHA, and lumefantrine were influenced by the presence of ketoconazole. AUC(0, infinity ) was increased from 320 to 740 ng ml-1 h (ratio 2.4, 90% CI 2.00, 2.86) for artemether, from 331 to 501 ng ml-1 h (ratio 1.7, 90% CI 1.40, 1.98) for DHA, and from 207 to 333 micro g ml-1 h (ratio 1.7, 90% CI 1.23, 2.21) for lumefantrine in the presence of ketoconazole. Cmax also increased in similar proportions for the three compounds (ratio 2.2 (90% CI 1.78, 2.83), 1.4 (90% CI 1.12, 1.74), and 1.3 (90% CI 0.96, 1.64), respectively). The terminal elimination half-life was increased for artemether (2.5 vs 1.9 h, 90% CI 1.12, 1.72) and DHA (3.1 vs 2.1 h, 90% CI 0.02, 3.36), but remained unchanged for lumefantrine (88 vs 95 h, 90% CI 0.81, 1.04). These increases in exposure to the antimalarial combination were much smaller than observed with food intake (up to 16 fold), and were not associated with increased side-effects or changes in electrocardiographic parameters. The study medications were well tolerated. CONCLUSIONS: The concurrent administration of ketoconazole with co-artemether led to modest increases in artemether, DHA, and lumefantrine exposure in healthy subjects. Dose adjustment of co-artemether is probably unnecessary in falciparum malaria patients when administered in association with ketoconazole or other potent CYP3A4 inhibitors.
RCT Entities:
AIMS: To evaluate whether the potent CYP3A4 inhibitor ketoconazole has any influence on the pharmacokinetic and electrocardiographic parameters of the antimalarial co-artemether (artemether-lumefantrine) in healthy subjects. METHODS: Sixteen subjects were randomized in an open-label, two period crossover design study. Subjects received a single dose of co-artemether (day 1) either alone or in combination with multiple oral doses of ketoconazole (400 mg on day 1 followed by 200 mg o.d. for 4 additional days). Serial blood samples were taken and assayed for artemether and its main active metabolite dihydroartemisinin (DHA), and lumefantrine. RESULTS: The pharmacokinetics of artemether, its metabolite DHA, and lumefantrine were influenced by the presence of ketoconazole. AUC(0, infinity ) was increased from 320 to 740 ng ml-1 h (ratio 2.4, 90% CI 2.00, 2.86) for artemether, from 331 to 501 ng ml-1 h (ratio 1.7, 90% CI 1.40, 1.98) for DHA, and from 207 to 333 micro g ml-1 h (ratio 1.7, 90% CI 1.23, 2.21) for lumefantrine in the presence of ketoconazole. Cmax also increased in similar proportions for the three compounds (ratio 2.2 (90% CI 1.78, 2.83), 1.4 (90% CI 1.12, 1.74), and 1.3 (90% CI 0.96, 1.64), respectively). The terminal elimination half-life was increased for artemether (2.5 vs 1.9 h, 90% CI 1.12, 1.72) and DHA (3.1 vs 2.1 h, 90% CI 0.02, 3.36), but remained unchanged for lumefantrine (88 vs 95 h, 90% CI 0.81, 1.04). These increases in exposure to the antimalarial combination were much smaller than observed with food intake (up to 16 fold), and were not associated with increased side-effects or changes in electrocardiographic parameters. The study medications were well tolerated. CONCLUSIONS: The concurrent administration of ketoconazole with co-artemether led to modest increases in artemether, DHA, and lumefantrine exposure in healthy subjects. Dose adjustment of co-artemether is probably unnecessary in falciparum malariapatients when administered in association with ketoconazole or other potent CYP3A4 inhibitors.
Authors: N A Kshirsagar; N J Gogtay; N S Moorthy; M R Garg; S S Dalvi; A R Chogle; J S Sorabjee; S N Marathe; G H Tilve; A D Bhatt; S P Sane; R Mull; I Gathmann Journal: Am J Trop Med Hyg Date: 2000-03 Impact factor: 2.345
Authors: L von Seidlein; S Jaffar; M Pinder; M Haywood; G Snounou; B Gemperli; I Gathmann; C Royce; B Greenwood Journal: J Infect Dis Date: 1997-10 Impact factor: 5.226
Authors: G Lefèvre; S Looareesuwan; S Treeprasertsuk; S Krudsood; U Silachamroon; I Gathmann; R Mull; R Bakshi Journal: Am J Trop Med Hyg Date: 2001 May-Jun Impact factor: 2.345
Authors: T K Daneshmend; D W Warnock; M D Ene; E M Johnson; M R Potten; M D Richardson; P J Williamson Journal: Antimicrob Agents Chemother Date: 1984-01 Impact factor: 5.191
Authors: R E Polk; M A Crouch; D S Israel; A Pastor; B M Sadler; G E Chittick; W T Symonds; W Gouldin; Y Lou Journal: Pharmacotherapy Date: 1999-12 Impact factor: 4.705
Authors: Joel Tarning; Rose McGready; Niklas Lindegardh; Elizabeth A Ashley; Mupawjay Pimanpanarak; Benjamas Kamanikom; Anna Annerberg; Nicholas P J Day; Kasia Stepniewska; Pratap Singhasivanon; Nicholas J White; François Nosten Journal: Antimicrob Agents Chemother Date: 2009-06-29 Impact factor: 5.191
Authors: Sam Salman; Madhu Page-Sharp; Susan Griffin; Kaye Kose; Peter M Siba; Kenneth F Ilett; Ivo Mueller; Timothy M E Davis Journal: Antimicrob Agents Chemother Date: 2011-08-29 Impact factor: 5.191
Authors: T Kredo; K Mauff; J S Van der Walt; L Wiesner; G Maartens; K Cohen; P Smith; K I Barnes Journal: Antimicrob Agents Chemother Date: 2011-09-26 Impact factor: 5.191